Description
Background:
Pertuzumab, sold under brand name PERJETA, is a monoclonal antibody used in combination with Trastuzumab and Docetaxel for the treatment of metastatic HER2-positive breast cancer. It is also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.A first-in-class of a kind of drug called a HERdimerization inhibitor, Pertuzumab inhibits thedimerizationof HER2 with other HER receptors, which prevents them from signallingin ways that promote cell growth and proliferation.
Intended Use:
For Estimation of Pertuzumab (PERJETA) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle of the assay: The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Pertuzumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Pertuzumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti- Pertuzumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Pertuzumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!